Cardiac muscle cell autophagy

“Cardiac muscle cell autophagy” refers to the cellular process by which cardiomyocytes (heart muscle cells) degrade and recycle protein aggregates, damaged organelles, and other cytoplasmic components through the lysosomal pathway. This process is essential for maintaining cardiac cellular homeostasis, energy adaptation under metabolic stress, and mitochondrial quality control[1][3][5][6][9]. Defective autophagy in cardiomyocytes is implicated in a range of cardiovascular diseases including cardiac hypertrophy, heart failure, ischemic injury, aging, and genetic cardiomyopathies (such as Danon disease)[1][3][7][9]. Autophagy is regulated by a core set of ATG proteins (e.g. Atg5, Atg7, Beclin-1), and signaling pathways including mTOR, PI3K/AKT, AMPK, MAPK, and calcium/calcineurin[2][4][5][6]. While autophagy in cardiac muscle cells is a critical cell biological process and a disease mechanism, it is not a discrete druggable molecular target (such as a specific protein or receptor), but rather a process or pathway that may include multiple potential molecular targets within its network[2][4][5]. Summary of why this is marked incorrect as a canonical target: “Cardiac muscle cell autophagy” describes a complex cellular process, not a single, specific molecular target (e.g., protein, receptor, ion channel), and cannot be considered a canonical therapeutic target for drug discovery or pharmacological intervention. It is better classified as a pathway or set of processes involving various molecular effectors (such as Beclin-1, mTOR, Atg proteins), which themselves might constitute canonical targets.

Other names

Cardiomyocyte autophagyAutophagy in cardiac muscle cellCardiac autophagyCardiomyocyte macroautophagy

Activation or inhibition of autophagy pathways (e.g., via mTOR inhibition by rapamycin) Modulation of Beclin-1/class III PI3K pathway Impact on upstream regulators such as AMPK, PI3K/AKT, MAPK